• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Article

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos
Manjool Shah, MD
A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.
Jennifer Snow, MPA, NAMI
Jennifer Snow, MPA, NAMI
Dr Debra Patt
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Dr Marco del Riccio
Dr Marco del Riccio
Eleanor Perfetto, PhD
Related Content
The OCEANIC-STROKE subgroup analysis findings, in tandem with the main results presented at ISC 2026, suggest that targeting factor XIa could be a safe way to intensify antithrombotic therapy following noncardioembolic stroke, regardless of underlying etiology. | Image credit: jolygon - stock.adobe.com

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

February 6th 2026
Article

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

Read More

Managed Care Cast Square Image

The Orphan Drug Act in the Modern Drug Pricing Era

February 3rd 2026
Podcast

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Drug pricing | Image Credit: © TarikVision-stock.adobe.com

TrumpRx Launch Brings Savings—and Uncertainty

February 5th 2026
Article

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions.

Read More

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

January 20th 2026
Podcast

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Asundexian with standard antiplatelet therapy helped reduce the chances of a recurrent stroke without increasing the risk of bleeding, according to the OCEANIC-STROKE trial. | Image credit: Studio Multiverse - stock.adobe.com

Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

February 5th 2026
Article

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

Read More

Insulin syringe | Image Credit: © ixel-Shot-stock.adobe.com

Express Scripts Avoids Fines but Agrees to Major Structural Overhaul

February 5th 2026
Article

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.